The news desk
What changed, what the source actually says, and what it does not prove. Older methods explainers are clearly dated.
7 updates
ClinicalTrials.gov lists a planned Phase 1 shoulder study as not yet recruiting. A separate Phase 2 hamstring-study record, last updated 27 February 2026, reports recruiting. Neither record has posted results.
Limits: These are registry-reported statuses, not independent confirmation of recruitment or evidence of benefit. The shoulder record contains conflicting enrollment and sham-procedure descriptions; those details remain unresolved.
Lilly announced topline results from TRIUMPH-1, a Phase 3 trial of retatrutide in adults with obesity or overweight. The announcement describes an 80-week main trial and reports that primary and key secondary endpoints were met.
Limits: This update covers the sponsor announcement, not a full published-study review or a current regulatory-status check. An announcement is not approval and does not validate a research supplier's material.
FDA revised its pyrogen and endotoxin testing guidance to accommodate a broader scope of recombinant reagents. Its explanation emphasizes verifying that the selected assay is suitable for the intended purpose and material.
Limits: This is guidance for FDA-regulated drugs and devices, not certification of a research supplier. The reagent name alone does not establish method suitability, sterility, or clinical safety.
FDA listed several peptide bulk substances for discussion at its July 2026 Pharmacy Compounding Advisory Committee meeting. An agenda, a committee recommendation, a compounding-list decision, and approval of a finished drug are different documents.
Limits: This article verifies the published agenda, not meeting votes, final listing decisions, or the current legal status of every named substance. It is a document-reading guide, not legal advice.
Read the full articleTwo August 2026 FDA warning letters explain why research-use labels did not outweigh the agency’s assessment of the sellers’ wider website presentation. The records concern stated regulatory violations, not laboratory findings about the materials.
Limits: These are agency allegations and requests for corrective action, not a current compliance audit or court ruling. FDA says subsequent interactions can change a recipient’s regulatory status.
Read the full articleAn international synthetic-oxytocin comparison illustrates why impurity identification, measurement method, and uncertainty belong beside a purity result. This is a methods explainer using clearly dated research, not a new 2026 product test.
Limits: The comparison concerns a reference material and participating metrology laboratories. It does not establish the quality of commercial peptide lots or show that every difference between laboratory results is acceptable.
Read the full articleLaboratory accreditation has a defined scope. ILAC guidance explains why the specific accredited activities matter, while separate decision-rule guidance shows why a pass statement also needs a specification and reporting context.
Limits: These sources explain accreditation and conformity-reporting concepts. This article has not verified any supplier’s laboratory, accreditation status, scope, or individual test report.
Read the full articleNo updates match this filter.